Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

A 3-D image shows a T cell expressing the immune checkpoint receptor PD-1 (green) interacting with an antigen presenting cell expressing the ligand PD-L1 (magenta).

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

PD-L1 is a cell surface receptor expressed on both tumour and regulatory ... given as a monotherapy or in combination with MSD’s PD-1 inhibitor Keytruda (pembrolizumab), a widely-used treatment ...

and Palobiofarma’s adenosine A2A receptor inhibitor taminadenant (NIR178) in various cancer indications. With six PD-1/PD-L1 inhibitors on the market – and the most recent entrants struggling ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

The PD-1 protein functions as a type of off switch that prevents immune cells from attacking other cells. It is a “checkpoint” receptor that frequently appears on the surface of immune system ...

Tharimmune (THAR) announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both ...